Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Companies

Top Ten Companies // Browse A - Z of companies

  • Merck KGaA (Merck)
  • Merck (Merck KGaA)
  • Pfizer
  • Roche
  • Novartis
  • GlaxoSmithKline (GSK)
  • GSK (GlaxoSmithKline)
  • Bristol-Myers Squibb
  • Lilly
  • Bayer

Browse the A - Z of Companies

  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

K

  • K-V Pharmaceutical
  • KAI Pharmaceuticals
  • Kaken Pharma
  • Kaketsuken
  • Kalbe Pharma
  • KaloBios Pharmaceuticals
  • KalVista Pharmaceuticals
  • Kamada
  • Kanghong Sagent (Chengdu) Pharmaceutical
  • Karalex Pharma
  • Karo Bio
  • Karolinska Development
  • KDR Biotech
  • Kemira
  • Kemwell
  • Kent Pharmaceutical
  • Keryx Biopharmaceuticals
  • Kevelt
  • Kiadis Pharma
  • Kilitch Drugs
  • Kinex Pharmaceuticals
  • King Pharmaceuticals
  • Kitov Pharmaceuticals
  • Knome
  • Knopp Neurosciences
  • Kony Pharma
  • Korea Kolmar
  • Kos Pharmaceuticals
  • Kowa Pharmaceuticals
  • Kunwha Pharma
  • Kusum Pharma
  • KV Pharmaceutical
  • Kwang Dong Pharmaceutical
  • Kymab
  • Kyorin Pharmaceuticals
  • Kyowa Hakko
  • Kyowa Hakko Kirin
  • Kyowa Pharmaceuticals
  • KYTHERA
  • KYTHERA Biopharmaceuticals
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS